AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the safety, tolerability and preliminary efficacy of
AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).